ProSomnus Inc

Prosomnus, Inc. is a medical technology company. It engages in the development, manufacture and marketing of precision intraoral medical devices. The company is headquartered in Wilmington, DE.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prosomnus, Inc. is a medical technology company, which engages in the business of developing, manufacturing, and marketing precision intraoral medical devices. It focuses on treating and managing patients with obstructive sleep apnea. The company was founded by Leonard Liptak and Sung Kim in 2006 and is headquartered in Pleasanton, CA.

Company commences execution of strategic growth initiatives following Initial Public Offering Company commences execution of strategic growth initiatives following Initial Public Offering

ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance

Data from First Line Obstructive Sleep Apnea Treatment Study (FLOSAT) study will be presented for the first time Data from First Line Obstructive Sleep Apnea Treatment Study (FLOSAT) study will be presented for the first time

ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference

First prospective crossover study comparing the effectiveness of precision oral appliance therapy as front-line therapy relative to CPAP for the treatment of obstructive sleep apnea

ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital's First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)

Additional reimbursement coverage further expands the market for ProSomnus as the Company seeks to make precision oral appliance therapy a first-line treatment for obstructive sleep apnea Additional reimbursement coverage further expands the market for ProSomnus as the Company seeks to make precision oral appliance therapy a first-line treatment for obstructive sleep apnea

ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device

SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. (“Lakeshore”) (Nasdaq: LAAA), a publicly traded special purpose acquisition company. ProSomnus will commence trading on the Nasdaq Global Market under the symbol “OSA” on Dec. 7, 2022. The business combination, which was approved by Lakeshore's shareholders on Dec. 2, 2022, along with the convertible debt issued in connection with the transaction, provides access to capital that will be used to drive the Company's multi-faceted commercial expansion.

ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices

News for ProSomnus Inc Stock (OSA)